Atazanavir and Cobicistat
EVOTAZ
Cytochrome P450 3A Inhibitor
NADAC/unit
$51.9785
No Shortage
Tier 1: 17.9%
vs. brand EVOTAZ: Generic saves up to -420% per unit
Active Shortages
2025-11-03 The global Cease Manufacture date for EVOTAZ® currently is estimated to begin April 2026., Bristol Myers Squibb Co.
Generic Manufacturers
BRISTOL MYERS SQUIBB CO
Explore in the Ecosystem
Data sourced from CMS NADAC, FDA Orange Book, CMS Part D Formulary, CMS Part D Spending, openFDA, and HRSA 340B OPAIS. Prices reflect National Average Drug Acquisition Cost and may not represent actual transaction prices. This information is for research and comparison purposes only. Consult your pharmacist or benefits consultant for plan-specific pricing.